IP Library Granted Patent US 9,561,216
Granted Patent B2
US 9,561,216 · App. 14/972,362 · Granted Feb 7, 2017

Alkylamine derivative

Inventors: Masayuki Sugiki (Kawasaki, JP); Toru Okamatsu (Kawasaki, JP); Tetsuo Yano (Kawaskai, JP); Shinya Taniguchi (Kanagawa, JP)
Assignee: EA Pharma Co., Ltd.
A61K31/4402A23L27/202A23L27/204A61K31/185A61K31/198A61K31/27A61K31/4045A61K31/417A61K31/4245A61K31/44A61K31/5375C07C275/42C07C309/51C07C311/32C07C311/51C07C333/08C07C335/16C07D209/14C07D213/74C07D213/75C07D233/61C07D271/10C07D295/16C07D295/192C07D413/04C07C2101/14C07C2101/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,561,216
App. No.
14/972,362
Granted
Feb 7, 2017
Kind
B2
Abstract

A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi.

Claims (63)

1. A method of activating CaSR, comprising:

administering a compound of Formula (I 0 ) or a pharmaceutically acceptable salt thereof:

wherein R 1 and R 2 , each independently, represent a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl or substituted or unsubstituted C 2-6 alkynyl, or R 1 and R 2 may integrally form a substituted or unsubstituted 5- or 6-membered hetero ring which may further include a heteroatom(s);

R 3 represents a hydrogen atom, halogeno or substituted or unsubstituted C 1-6 alkyl;

R 4 and R 5 , each independently, represent a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl or halogeno;

X represents NH;

Y represents C═O, SO, SO 2 , C═S or C═NR d , where R d represents a hydrogen atom or C 1-6 alkyl, and R d and R 6 may integrally form a substituted or unsubstituted 5- or 6-membered hetero ring;

R 6 represents a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl or hydroxy;

G 0 represents unsubstitued or substituted aryl with one or more R 70 or unsubstitued or substituted heteroaryl with one or more R 70 , where the R 70 -substituted aryl or the R 70 -substituted heteroaryl may further be substituted, where aryl in G 0 is phenyl or naphthyl, and heteroaryl in G 0 is one of pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, furyl, thiophenyl and pyrrolyl;

R 70 represents substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, halogeno, hydroxy, substituted or unsubstituted C 1-6 alkoxy, nitro, amino, mono-C 1-6 alkylamino, di-C 1-6 alkylamino, sulfo, carboxyl, phosphono, C 1-3 alkylcarbonylamino or mono-C 1-6 alkylphosphono, where they may be different when more than one R 70 exist;

Q represents a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, carboxyl, CONR e R f , CONHNHR g , COR h , substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

R e and R f , each independently, represent a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkylsulfonyl, substituted or unsubstituted arylsulfonyl, substituted or unsubstituted C 3-8 cycloalkyl, hydroxy or C 1-6 alkoxy, or alternatively, R e and R f may integrally form a substituted or unsubstituted 5- or 6-membered hetero ring which may further have a heteroatom(s);

R g represents substituted or unsubstituted C 1-6 alkylcarbonyl, substituted or unsubstituted benzoyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

R h represents substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted mercapto, or the following group:

where Z represents a bivalent group of substituted or unsubstituted C 1-6 hydrocarbon; E 1 represents substituted or unsubstituted C 1-6 acyloxy, substituted or unsubstituted C 1-6 alkoxycarbonyloxy, substituted or unsubstituted amino, carboxyl, substituted or unsubstituted C 1-6 alkoxycarbonyl, halogeno, aryl, heteroaryl, substituted or unsubstituted C 1-6 alkoxy or substituted or unsubstituted carbamoyl; E 2 represents a hydrogen atom or C 1-6 alkyl; and Z and E 1 may integrally form a ring.

2. The method according to claim 1 , wherein

G 0 represents substituted aryl with one or more R 70 or substituted heteroaryl with one or more R 70 , where the R 70 -substituted aryl or the R 70 -substituted heteroaryl may further be substituted; and

R 70 represents substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, halogeno, hydroxy, substituted or unsubstituted C 1-6 alkoxy, nitro, amino, mono-C 1-6 alkylamino, di-C 1-6 alkylamino, sulfo, carboxyl, phosphono or mono-C 1-6 alkylphosphono, where they may be different when more than one R 70 exist.

3. A method of treating a disease that is ameliorated through CaSR activation, comprising:

administering a compound of Formula (I 0 ) or a pharmaceutically acceptable salt thereof:

wherein R 1 and R 2 , each independently, represent a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl or substituted or unsubstituted C 2-6 alkynyl, or R 1 and R 2 may integrally form a substituted or unsubstituted 5- or 6-membered hetero ring which may further include a heteroatom(s);

R 3 represents a hydrogen atom, halogeno or substituted or unsubstituted C 1-6 alkyl;

R 4 and R 5 , each independently, represent a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl or halogeno;

X represents NH;

Y represents C═O, SO, SO 2 , C═S or C═NR d , where R d represents a hydrogen atom or C 1-6 alkyl, and R d and R 6 may integrally form a substituted or unsubstituted 5- or 6-membered hetero ring;

R 6 represents a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl or hydroxy;

G 0 represents unsubstitued or substituted aryl with one or more R 70 or unsubstitued or substituted heteroaryl with one or more R 70 , where the R 70 -substituted aryl or the R 70 -substituted heteroaryl may further be substituted, where aryl in G 0 is phenyl or naphthyl, and heteroaryl in G 0 is one of pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, furyl, thiophenyl and pyrrolyl;

R 70 represents substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, halogeno, hydroxy, substituted or unsubstituted C 1-6 alkoxy, nitro, amino, mono-C 1-6 alkylamino, di-C 1-6 alkylamino, sulfo, carboxyl, phosphono, C 1-3 alkylcarbonylamino or mono-C 1-6 alkylphosphono, where they may be different when more than one R 70 exist;

Q represents a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, carboxyl, CONR e R f , CONHNHR g , COR h , substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

R e and R f , each independently, represent a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkylsulfonyl, substituted or unsubstituted arylsulfonyl, substituted or unsubstituted C 3-8 cycloalkyl, hydroxy or C 1-6 alkoxy, or alternatively, R e and R f may integrally form a substituted or unsubstituted 5- or 6-membered hetero ring which may further have a heteroatom(s);

R g represents substituted or unsubstituted C 1-6 alkylcarbonyl, substituted or unsubstituted benzoyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

R h represents substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted mercapto, or the following group:

where Z represents a bivalent group of substituted or unsubstituted C 1-6 hydrocarbon; E 1 represents substituted or unsubstituted C 1-6 acyloxy, substituted or unsubstituted C 1-6 alkoxycarbonyloxy, substituted or unsubstituted amino, carboxyl, substituted or unsubstituted C 1-6 alkoxycarbonyl, halogeno, aryl, heteroaryl, substituted or unsubstituted C 1-6 alkoxy or substituted or unsubstituted carbamoyl; E 2 represents a hydrogen atom or C 1-6 alkyl; and Z and E 1 may integrally form a ring.

4. The method according to claim 3 , wherein

G 0 represents substituted aryl with one or more R 70 or substituted heteroaryl with one or more R 70 , where the R 70 -substituted aryl or the R 70 -substituted heteroaryl may further be substituted; and

R 70 represents substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, halogeno, hydroxy, substituted or unsubstituted C 1-6 alkoxy, nitro, amino, mono-C 1-6 alkylamino, di-C 1-6 alkylamino, sulfo, carboxyl, phosphono or mono-C 1-6 alkylphosphono, where they may be different when more than one R 70 exist.

5. The method according to claim 3 , wherein the disease is hyperparathyroidism.

6. The method according to claim 4 , wherein the disease is hyperparathyroidism.

7. The method according to claim 3 , wherein the disease is diarrhea.

8. The method according to claim 4 , wherein the disease is diarrhea.

9. The method according to claim 3 , wherein the disease is peptic ulcer.

10. The method according to claim 4 , wherein the disease is peptic ulcer.

11. A method of activating CaSR, comprising:

administering a composition including a compound of Formula (I 0 ) or an edible salt thereof:

wherein the composition is a seasoning or a kokumi-imparting agent;

R 1 and R 2 , each independently, represent a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl or substituted or unsubstituted C 2-6 alkynyl, or R 1 and R 2 may integrally form a substituted or unsubstituted 5- or 6-membered hetero ring which may further include a heteroatom(s);

R 3 represents a hydrogen atom, halogeno or substituted or unsubstituted C 1-6 alkyl;

R 4 and R 5 , each independently, represent a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl or halogeno;

X represents NH;

Y represents C═O, SO, SO 2 , C═S or C═NR d , where R d represents a hydrogen atom or C 1-6 alkyl, and R d and R 6 may integrally form a substituted or unsubstituted 5- or 6-membered hetero ring;

R 6 represents a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl or hydroxy;

G 0 represents unsubstitued or substituted aryl with one or more R 70 or unsubstitued or substituted heteroaryl with one or more R 70 , where the R 70 -substituted aryl or the R 70 -substituted heteroaryl may further be substituted, where aryl in G 0 is phenyl or naphthyl, and heteroaryl in G 0 is one of pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, furyl, thiophenyl and pyrrolyl;

R 70 represents substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, halogeno, hydroxy, substituted or unsubstituted C 1-6 alkoxy, nitro, amino, mono-C 1-6 alkylamino, di-C 1-6 alkylamino, sulfo, carboxyl, phosphono, C 1-3 alkylcarbonylamino or mono-C 1-6 alkylphosphono, where they may be different when more than one R 70 exist;

Q represents a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, carboxyl, CONR e R f , CONHNHR g , COR h , substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

R e and R f , each independently, represent a hydrogen atom, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkylsulfonyl, substituted or unsubstituted arylsulfonyl, substituted or unsubstituted C 3-8 cycloalkyl, hydroxy or C 1-6 alkoxy, or alternatively, R e and R f may integrally form a substituted or unsubstituted 5- or 6-membered hetero ring which may further have a heteroatom(s);

R g represents substituted or unsubstituted C 1-6 alkylcarbonyl, substituted or unsubstituted benzoyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

R h represents substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted mercapto, or the following group:

where Z represents a bivalent group of substituted or unsubstituted C 1-6 hydrocarbon; E 1 represents substituted or unsubstituted C 1-6 acyloxy, substituted or unsubstituted C 1-6 alkoxycarbonyloxy, substituted or unsubstituted amino, carboxyl, substituted or unsubstituted C 1-6 alkoxycarbonyl, halogeno, aryl, heteroaryl, substituted or unsubstituted C 1-6 alkoxy or substituted or unsubstituted carbamoyl; E 2 represents a hydrogen atom or C 1-6 alkyl; and Z and E 1 may integrally form a ring.

12. The method according to claim 11 , wherein

G 0 represents substituted aryl with one or more R 70 or substituted heteroaryl with one or more R 70 , where the R 70 -substituted aryl or the R 70 -substituted heteroaryl may further be substituted; and

R 70 represents substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, halogeno, hydroxy, substituted or unsubstituted C 1-6 alkoxy, nitro, amino, mono-C 1-6 alkylamino, di-C 1-6 alkylamino, sulfo, carboxyl, phosphono or mono-C 1-6 alkylphosphono, where they may be different when more than one R 70 exist.

13. The method according to claim 11 , wherein the composition is a seasoning.

14. The method according to claim 11 , wherein the composition is a kokumi-imparting agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2016
From: AJINOMOTO CO., INC.
To: EA PHARMA CO., LTD.
Reel/Frame 039094/0087 →
Priority Claims (1)
JP 2010-048310 · Mar 4, 2010 · national
Continuity (3)
Continuation 13600977 · Aug 31, 2012
Continuation PCTJP2011055033 · Mar 4, 2011
Related Publication 20160101091A1 · Apr 14, 2016